# OnKure Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/OnKure Therapeutics, Inc.). ## Overview OnKure Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases. Its pipeline centers on small-molecule drug candidates designed with structure-based drug design to selectively target mutated forms of biologically validated proteins, including PI3Kα. ## Products & services • Clinical-stage precision oncology drug candidates • Small-molecule inhibitors targeting mutated PI3Kα • Structure-based drug design and medicinal chemistry • Preclinical and clinical development programs • Intellectual property and translational research platform - **Clinical-stage drug candidates** (100%) — Investigational small-molecule therapies being advanced through preclinical and clinical development. - **PI3Kα-targeted programs** (0%) — Programs designed to selectively inhibit mutated PI3Kα drivers in cancer and related diseases. - **Drug discovery platform** (0%) — Structure-based discovery capabilities using medicinal chemistry, x-ray crystallography, and computation. - Clinical-stage precision oncology drug candidates - Small-molecule inhibitors targeting mutated PI3Kα - Structure-based drug design and medicinal chemistry - Preclinical and clinical development programs - Intellectual property and translational research platform ## Customers OnKure does not sell commercial products today; its near-term counterparties are research sites, CROs, manufacturers, regulators, and potential development collaborators. If approved, its eventual customers would be physicians, patients, hospitals, and third-party payors in oncology and related specialty markets. - **Clinical research organizations and trial sites** (primary) — They support the development of OKI-219 and future programs by running studies and generating clinical data. - **Regulatory authorities** (primary) — They review clinical, manufacturing, and safety data needed for marketing approval. - **Manufacturing and supply partners** (primary) — They provide drug substance, finished product, packaging, and scale-up support for development and launch. - **Potential future patients and physicians** (emerging) — They would use approved therapies for cancers and other diseases driven by specific mutations. - **Third-party payors** (emerging) — They determine coverage and reimbursement that would affect adoption of any approved product. - CROs and clinical sites running trials for product candidates - Regulators reviewing safety, efficacy, and approval packages - Manufacturing and supply partners supporting clinical and future launch - Potential collaborators or licensees in biopharma development - Future physicians, patients, and payors if a product is approved ## Geography OnKure is incorporated in Delaware and has its principal executive offices in Boulder, Colorado. Its business is primarily U.S.-based today, with future development, regulatory, and commercialization activities potentially extending internationally through patents, clinical operations, and market access. - Headquartered in Boulder, Colorado - Incorporated in Delaware - Clinical and regulatory activity is centered in the United States - Future patent protection and commercialization may extend internationally - Facilities are leased rather than owned ## Strategy OnKure’s strategy is to advance a focused pipeline of precision medicines built around mutated PI3Kα and related validated targets. The company is also building the clinical, manufacturing, intellectual property, and financing capabilities needed to move a drug candidate from discovery into approval and eventual commercialization. - **Advance OKI-219 through clinical development** (short-term) — The company is substantially dependent on this lead program for value creation. - **Develop additional product candidates** (medium-term) — A broader pipeline reduces single-asset dependence and expands long-term optionality. - **Establish manufacturing and commercialization readiness** (medium-term) — Biopharma value depends on scalable supply, launch capability, and market access if approved. - Advance OKI-219 through clinical development - Use structure-based design to improve selectivity and tolerability - Expand the pipeline beyond the lead program - Build manufacturing and clinical trial capabilities - Protect patents and exclusivity in key markets ## Risks OnKure faces the typical risks of a clinical-stage biotech: no approved products, no product revenue, and heavy dependence on successful clinical and regulatory outcomes. Its concentration in a lead asset, the need for additional capital, and the uncertainty of reimbursement and market acceptance all create substantial execution risk. - **Lead-asset concentration** [high] — The company is substantially dependent on OKI-219, so setbacks would materially harm the business. - **Clinical development failure** [high] — Drug candidates can fail to demonstrate efficacy, safety, or tolerability in trials. - **Regulatory approval risk** [high] — Approval depends on successful trial results, manufacturing readiness, and agency review. - **Financing risk** [high] — The company expects to need additional capital to fund operations and development. - **Commercialization and reimbursement risk** [medium] — Even approved therapies may face coverage, pricing, and adoption barriers. - No approved products and no product revenue today - Heavy dependence on OKI-219 as the lead value driver - Clinical trials may fail, delay, or show insufficient efficacy/safety - Additional capital will likely be needed to fund development - Future approval does not ensure reimbursement or market adoption ## Accounting As a clinical-stage biotech, OnKure’s reported results are driven mainly by R&D expense, stock-based compensation, and financing-related items rather than product revenue. Investors should watch lease accounting, capitalized versus expensed development costs, fair-value measurements for financing instruments, and estimates tied to clinical and regulatory milestones. - **Research and development expense** — Major driver of operating loss - **Lease accounting** — Occupancy and balance sheet presentation - **Fair value of financing instruments** — Financing gains/losses and dilution analysis - **Stock-based compensation** — Operating expense and dilution - No product revenue, so results are dominated by operating expense - R&D spending reflects clinical trials, manufacturing, and discovery work - Lease accounting affects occupancy costs and right-of-use assets - Equity and convertible debt financing can involve fair-value judgments - Stock-based compensation can materially affect reported expenses --- *Last updated: 2026-04-29T04:43:48.236176+00:00*